Fig. 3 | Nature Communications

Fig. 3

From: TRPV4 and KRAS and FGFR1 gain-of-function mutations drive giant cell lesions of the jaw

Fig. 3The alternative text for this image may have been generated using AI.

MAPK pathway activation in GCLJ. Immunohistochemical (IHC) staining for phospho-ERK1/2 shows strong positive staining in mononucleated cells in GCLJ lesions. Representative images of phospho-ERK1/2 staining in TRPV4 p.M713V (a), KRAS p.G12D (b), and FGFR1 p.C831R (c) mutant and in WT (d) GCLJ cases. e Immunoblot showing sustained phospho-ERK1/2 (pERK1/2) activation in TRPV4 M713I HEK293 mutant cells compared to WT. A representative experiment of three independent assays is provided. Scale bar represents 200 μm

Back to article page